产品
编 号：F622772
分子式：C27H33ClN6O2
分子量：509.04
分子式：C27H33ClN6O2
分子量：509.04
产品类型
规格
价格
是否有货
结构图
CAS No: 1549811-36-0
产品详情
生物活性：
BMS-P5 is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model.
体内研究：
BMS-P5 (50 mg/kg, oral gavage) significantly improves survival of MM-bearing mice.BMS-P5 (50 mg/kg, oral gavage) may attenuate the presence of pro-tumorigenic proteins in the tumor microenvironment, and thus delay tumor progression.Animal Model:Syngeneic mouse model of MM.
Dosage:50 mg/kg.
Administration:Oral gavage, twice a day beginning on day 3 after tumor cell injection.
Result:Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice.
体外研究：
BMS-P5 blocks calcium ionophore-induced citrullination of histone H3.BMS-P5 is also able to inhibit formation of NETs induced by primary MM cells isolated from the BM of patients with MM.
BMS-P5 is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model.
体内研究：
BMS-P5 (50 mg/kg, oral gavage) significantly improves survival of MM-bearing mice.BMS-P5 (50 mg/kg, oral gavage) may attenuate the presence of pro-tumorigenic proteins in the tumor microenvironment, and thus delay tumor progression.Animal Model:Syngeneic mouse model of MM.
Dosage:50 mg/kg.
Administration:Oral gavage, twice a day beginning on day 3 after tumor cell injection.
Result:Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice.
体外研究：
BMS-P5 blocks calcium ionophore-induced citrullination of histone H3.BMS-P5 is also able to inhibit formation of NETs induced by primary MM cells isolated from the BM of patients with MM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备